← Back to headlines
Corcept Therapeutics Stock Surges Following FDA Approval of Lifyorli
Corcept Therapeutics (CORT) shares climbed by 19.7% after its drug Lifyorli received approval from the FDA.
26 Mar, 01:01 — 26 Mar, 01:01
Sources
Showing 1 of 1 sources
